Tsubakihara Y, Hayashi T, Shoji T, Kitamura E, Okada N, Nakanishi I
Department of Nephrology, Osaka Prefectural Hospital, Japan.
Nihon Jinzo Gakkai Shi. 1994 Mar;36(3):246-9.
We evaluated saliva concentration as a parameter of therapeutic drug monitoring (TDM) of Ofloxacin (OFLX) in patients with severe renal failure (CRF). Saliva OFLX concentration correlated closely with serum OFLX concentration as shown in healthy subjects, although it was significantly lower (about three-quarters), indicating that OFLX had less penetration into saliva in patients with renal failure. Saliva concentration was almost equal to serum concentration during hemodialysis, which might have been due to the constant dialysis of OFLX. In conclusion, saliva concentration was useful for TDM of OFLX in patients with CRF, as it is in healthy subjects.
我们评估了重度肾衰竭（CRF）患者的唾液浓度，将其作为氧氟沙星（OFLX）治疗药物监测（TDM）的一个参数。与健康受试者的情况一样，唾液中OFLX浓度与血清中OFLX浓度密切相关，尽管唾液中OFLX浓度显著更低（约为四分之三），这表明肾衰竭患者中OFLX向唾液中的渗透较少。血液透析期间唾液浓度几乎与血清浓度相等，这可能是由于OFLX持续被透析。总之，与健康受试者一样，唾液浓度对CRF患者的OFLX TDM有用。
